Safety and Tolerability of Monoclonal Antibody Therapies for Treatment of COVID-19 in Pediatric Patients

Mak, Gregory; Dassner, Aimee; B, Hammer; Hanisch, Benjamin

doi:10.1097/inf.0000000000003263

Cited by 14 publications

(11 citation statements)

References 7 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In clinical studies, SARS-CoV-2 monoclonal antibodies reduced hospitalization and mortality in patients with mild and moderate COVID-19 who had risk factors for progression to severe COVID-19 [ 44 - 47 ]. Mak et al [ 48 ] reported that monoclonal antibody treatment appeared to be safe and effective in some child and adolescent COVID-19 patients.…”

Section: Anti-sars-cov-2 Monoclonal Antibodiesmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutics for the treatment of coronavirus disease 2019 in children and adolescents

Choi¹,

Choi²,

Yun³

2022

Clin Exp Pediatr

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is a mild to moderate respiratory illness in most children and adolescents, but a small proportion develop severe or critical illness. Although pediatric clinical trials for the treatment of COVID-19 are sparse, there are some available drugs for children and adolescents with severe COVID-19. This review summarizes clinical data focusing on antiviral agents and immunomodulators for COVID-19 treatment.Additionally, the current recommendations for therapeutics for children and adolescents with COVID-19 are discussed. Remdesivir is suggested for pediatric patients with COVID-19 in the following cases: children and adolescents with severe COVID-19 who need supplemental oxygen without mechanical ventilation; adolescents aged ≥12 years and weight of at least 40 kg with COVID-19 who do not require supplemental oxygen and are within 7 days of symptom onset and are at high risk of progression to severe illness. Nirmatrelvir/ritonavir is considered for adolescents aged ≥12 years and weighing at least 40 kg who do not require supplemental oxygen and are within 5 days of symptom onset and are at high risk of progression to severe disease. Corticosteroids are not recommended in children and adolescents with mild to moderate COVID-19. Corticosteroids are recommended in children and adolescents with severe to critical COVID-19.

show abstract

Section: Anti-sars-cov-2 Monoclonal Antibodiesmentioning

confidence: 99%

“… SARS-CoV-2 monoclonal antibodies authorized for COVID-19 treatment in children and adolescents [ 48 ] …”

Section: Supplementary Materialsmentioning

confidence: 99%

Therapeutics for the treatment of coronavirus disease 2019 in children and adolescents

Choi¹,

Choi²,

Yun³

2022

Clin Exp Pediatr

View full text Add to dashboard Cite

show abstract

“…There is a paucity of data on the efficacy and tolerability of MCA therapy in pediatric patients as little research has been conducted in this patient population. Mak and colleagues recently published their experience using MCA therapy in 17 pediatric patients and reported that treatment was well-tolerated and may be effective in limiting progression to more severe disease, though this is the first preliminary report published in this area [20].…”

Section: Introductionmentioning

confidence: 99%

The use of monoclonal antibody therapy in pediatric patients with COVID-19: a retrospective case series

et al. 2022

View full text Add to dashboard Cite

Background Monoclonal antibody (MCA) therapies have been utilized under emergency use authorization (EUA) for high-risk pediatric patients with mild to moderate coronavirus disease 2019 (COVID-19) in the outpatient setting since late 2019. The purpose of this study was to describe the use of MCA therapy in pediatric patients in the pediatric emergency department (ED) at a large community hospital. Methods This was a retrospective case series of high-risk pediatric patients 12 to 17 years of age who received MCA therapy in the pediatric ED between December 8, 2020 and June 3, 2021. The primary outcome was to describe the patient characteristics, clinical presentation, and safety profile of the pediatric population that received MCA therapy. The secondary outcome was to describe the incidence of hospitalizations or ED visits up to 28 days following therapy. Results A total of 44 patients were included in the analysis. The median number of days of symptoms was 4 with 41% of patients having symptoms between 0 and 3 days at time of MCA administration. Only one patient experienced a mild adverse event that did not require epinephrine administration. Two patients returned to the ED for reevaluation during the study follow-up period. No patients required admission within 28 days post-therapy. Conclusions The administration of MCA therapy in high-risk pediatric patients in the pediatric ED was well-tolerated with subjective improvement noted in COVID-19 symptoms post-therapy. Further studies are necessary to determine the role MCA therapy may play in reducing morbidity from COVID-19 infection in high-risk pediatric patients.

show abstract

“…In May 2021, a group of experts, based on the evidence, suggested that routine administration of mAb therapy for treatment of COVID-19 in children or adolescents was not permissible [20]. Yet, a recent report by Mak et al showed a case-series of 17 patients with ages between 12 and 20 years old with COVID-19, who were treated with mAbs (bamlanivimab, bamlanivimab-etesevimab, casirivimab-imdevimab) [21] and the treatment was well-tolerated and safe, with no adverse reactions reported. To support this evidence, we report our experience of the administration of mAb as a treatment for COVID-19 in pediatric patients aged from 24 days to 18 years old.…”

Section: Introductionmentioning

confidence: 99%

Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection

et al. 2022

View full text Add to dashboard Cite

show abstract

Safety and Tolerability of Monoclonal Antibody Therapies for Treatment of COVID-19 in Pediatric Patients

Cited by 14 publications

References 7 publications

Therapeutics for the treatment of coronavirus disease 2019 in children and adolescents

Therapeutics for the treatment of coronavirus disease 2019 in children and adolescents

The use of monoclonal antibody therapy in pediatric patients with COVID-19: a retrospective case series

Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection

Contact Info

Product

Resources

About